



CLAIMS


1. A compound of Formula (I):



or a stereoisomer, a geometric isomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof,

each of A and A' is independently






wherein each X^1 is independently O, S, NR^6 , or CR^7R^{7a} ;

each X^2 is independently NR^6 , O or S;

each X^3 is independently O, S, NR^6 , $C(=O)$ or CR^7R^{7a} ;

X^4 is $(CR^7R^{7a})_n$, $\text{---}\overset{\text{Z}}{\underset{\text{Z}}{Y^1=Y^2}}\text{---}$, O, S or NR^6 ;



is carbocyclyl or heterocyclyl;

each Y^1 and Y^2 is independently N or CR^7 ;

Z is $-(CH_2)_a-$, $-\text{CH}=\text{CH}-$, $-\text{N}=\text{CH}-$, $-(CH_2)_a-\text{N}(R^5)-(CH_2)_b-$, or $-(CH_2)_a-\text{O}-(CH_2)_b-$,

wherein each a and b is independently 0, 1, 2 or 3;

each c is independently 1 or 2;

each d is independently 1 or 2;

e is 0, 1, 2, 3 or 4 with the proviso that where X^3 is O, S or NR^6 , e is 1;

f is 0, 1, 2, 3 or 4;

each of X and X' is independently N or CR^7 ;

each of Y and Y' is independently $-U-(CR^9R^{9a})_t-R^{12}$;

each U is independently $-C(=O)-$ or $-C(=S)-$;

each t is independently 1;

each k is independently 0, 1 or 2;

R^1 and R^2 , together with X-CH they are attached to, optionally form a 3-8 membered heterocycle or carbocycle, C_{5-12} fused bicycle, C_{5-12} fused heterobicycle, C_{5-12} spiro bicycle or C_{5-12} spiro heterobicycle; or R^3 and R^4 , together with X'-CH they are attached to, optionally form a 3-8 membered heterocycle or carbocycle, C_{5-12} fused bicycle, C_{5-12} fused heterobicycle, C_{5-12} spiro bicycle or C_{5-12} spiro heterobicycle;

each R^5 is independently H, deuterium, hydroxy, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, or alkoxy;

each R^{5a} is independently H, deuterium, oxo ($=O$), hydroxy, amino, F, Cl, Br, I, cyano, aryl, heteroaryl, alkoxy, alkylamino, alkyl, haloalkyl, alkenyl, alkynyl, heterocyclyl, cycloalkyl, mercapto, nitro, or aralkyl;

each R^6 is independently H, deuterium, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, or alkylthioaliphatic;

each R^{6a} is independently H, deuterium, hydroxy, amino, F, Cl, Br, I, cyano, alkyl, haloalkyl, alkenyl, alkynyl, heterocyclyl, cycloalkyl, mercapto, nitro, aralkyl, arylamino, heteroaryl amino, arylalkylamino, heteroarylalkylamino, heteroaryloxy, heteroarylalkyl, arylalkoxy, heteroarylalkoxy, heterocyclyloxy, heterocyclylalkoxy, heterocyclylamino, heterocyclylalkylamino, or aryloxy;

each R^7 and R^{7a} is independently H, deuterium, F, Cl, aliphatic, heteroalkyl,

haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, or alkylthioaliphatic;


each R^9 , R^{9a} , R^{10} and R^{11} is independently H, deuterium, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, haloalkyl, hydroxyalkyl, heteroarylalkyl, heterocyclalkyl, or cycloalkylalkyl;


each R^{12} is independently $-N(R^{13})C(=O)OR^{13a}$ or $-N(R^{13})C(=O)-R^{13a}$;

each R^{13} is H; and

each R^{13a} is H, deuterium, alkyl, heteroalkyl, or heterocyclyl;

wherein each of $-U-(CR^9R^{9a})_t-R^{12}$, NR^6 , CR^7R^{7a} , CR^7 , $-(CH_2)_a-$, $-CH=CH-$, $-N=CH-$, $-(CH_2)_a-N(R^5)-(CH_2)_b-$, alkyl, heteroalkyl, carbocyclyl, cycloalkyl, heterocyclyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, a group derived from α -amino acid, C_{5-12} fused bicycle, C_{5-12} fused heterobicycle, C_{5-12} spiro bicycle, C_{5-12} spiro heterobicycle, alkoxy, haloalkyl, alkenyl, alkynyl, arylamino, heteroarylamino, arylalkylamino, heteroarylalkylamino, heteroaryloxy, heteroarylalkyl, arylalkoxy, heteroarylalkoxy, heterocyclloxy, heterocyclalkoxy, heterocyclylamino, heterocyclalkylamino and aryloxy is optionally substituted with one or more substituents, wherein the substituent is deuterium, hydroxy, amino, halo, or cyano alkyl.





each Y^1 and Y^2 is independently N or CR^7 ;

each X^3 is independently O, S, NR^6 , $C(=O)$ or CR^7R^{7a} ;

each X^5 is independently CR^7R^{7a} , O, S or NR^6 ;

each Q^1 and Q^2 is independently NR^6 , O, S, $C(=O)$, or CR^7R^{7a} ;

each Q^3 is independently N or CR^7 ;


each e is independently 0, 1, 2, 3 or 4 with the proviso that where X^3 is O, S or NR^6 , e is 1;

each f is independently 0, 1, 2 or 3;

each R^{5a} is independently H, deuterium, hydroxy, amino, F, Cl, Br, I, cyano, C_{1-6} alkoxy, C_{1-6} alkylamino, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{2-10} heterocyclyl, C_{3-8} cycloalkyl, mercapto, nitro, C_{6-10} aralkyl, C_{6-10} arylamino, C_{1-9} heteroaryl, C_{6-10} aryl- C_{1-6} -alkylamino, C_{1-9} heteroaryl- C_{1-6} -alkylamino, C_{1-9} heteroaryloxy, C_{1-9} heteroaryl- C_{1-6} -alkyl, C_{6-10} aryl- C_{1-6} -alkoxy, C_{1-9} heteroaryl- C_{1-6} -alkoxy, C_{2-10} heterocyclyloxy, C_{2-10} heterocyclyl- C_{1-6} -alkoxy, C_{2-10} heterocyclylamino, C_{2-10} heterocyclyl- C_{1-6} -alkylamino or C_{6-10} aryloxy;


each R^6 is independently H, deuterium, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy- C_{1-6} -alkyl, C_{1-6} alkylamino- C_{1-6} -alkyl, or C_{1-6} alkylthio- C_{1-6} -alkyl; and

each R^7 and R^{7a} is independently H, deuterium, F, Cl, C_{1-6} alkyl, C_{1-6} heteroalkyl, or C_{1-6} haloalkyl.



3. The compound according to claim 2, wherein

is




wherein each R^{5a} is independently H, deuterium, oxo (=O), hydroxy, amino, F, Cl, Br, I, cyano, C_{1-6} alkoxy, C_{1-6} alkyl, C_{6-10} aryl, $-CF_3$, $-OCF_3$ nitro, or C_{1-6} alkylamino;

each Y^1 and Y^2 is independently N or CR^7 ;


each X^5 is independently CR^7R^{7a} , O, S, $C(=O)$ or NR^6 ;


each f is independently 0, 1, 2 or 3; and

each R^6 is independently H, deuterium, C_{1-4} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, or C_{1-6} alkoxy- C_{1-4} -alkyl.



4. The compound according to claim 3, wherein is






wherein each R^{5a} is independently H, deuterium, oxo ($=O$), hydroxy, amino, F, Cl, Br, I, cyano, C_{1-4} alkyl, $-CF_3$, $-OCF_3$, mercapto, nitro, or C_{1-4} alkylamino;


each Y^1 and Y^2 is independently N or CH;

each X^5 is independently CH_2 , O, S or NR^6 ; and

each R^6 is independently H, deuterium, C_{1-4} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, or C_{1-6} alkoxy- C_{1-4} -alkyl.

5. The compound according to claim 1, wherein each of A and A' is independently






wherein each R^5 is independently H, deuterium, hydroxy, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{3-8} cycloalkyl, C_{2-10} heterocyclyl, C_{6-10} aryl, C_{1-9} heteroaryl, C_{6-10}

each R^{6a} is independently H, deuterium, oxo (=O), hydroxy, amino, F, Cl, Br, I, cyano, C₆₋₁₀ aryl, C₁₋₉ heteroaryl, C₁₋₆ alkoxy, C₁₋₆ alkylamino, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₂₋₁₀ heterocyclyl, C₃₋₈ cycloalkyl, mercapto, nitro, C₆₋₁₀ aryl-C₁₋₆-alkyl, C₆₋₁₀ arylamino, C₁₋₉ heteroarylamino, or C₆₋₁₀ aryloxy;

each R⁸ and R^{8a} is independently H, deuterium, hydroxy, cyano, nitro, F, Cl, Br, I, C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₀ heterocyclyl, C₆₋₁₀ aryl, C₁₋₉ heteroaryl, C₆₋₁₀ aryl-C₁₋₆-alkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl-OC(=O)-, C₁₋₆ alkyl-C(=O)-, carbamoyl, C₁₋₆ alkyl-OS(=O)_r-, C₁₋₆ alkyl-S(=O)_rO-, C₁₋₆ alkyl-S(=O)_r-, or aminosulfonyl.

[illegible]



wherein X^1 is O or S;

each Y^1 is N or CR^7 ;


each R^6 is independently H, deuterium, C_{1-4} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy- C_{1-4} -alkyl, C_{1-6} alkylamino- C_{1-4} -alkyl, or C_{1-6} alkylthio- C_{1-4} -alkyl;

each R^{6a} is independently H, deuterium, oxo (=O), hydroxy, amino, F, Cl, Br, I,

cyano, R^7R^7N -, C_{1-6} alkoxy, C_{1-6} alkylamino, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, mercapto or nitro; and

each R^7 and R^{7a} is independently H, deuterium, F, Cl, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{1-6} haloalkyl, hydroxy C_{1-6} alkyl, amino C_{1-6} alkyl, C_{1-6} alkoxy- C_{1-6} -alkyl, C_{1-6} alkylamino- C_{1-6} -alkyl, or C_{1-6} alkylthio- C_{1-6} -alkyl.

7. The compound according to claim 1, wherein the R^1 , R^2 and X-CH together form one of the following monovalent groups:




wherein each R^{15} is independently H, deuterium, F, Cl, Br, I, cyano, hydroxy, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy, C_{1-3} alkylamino, C_{1-3} alkylthio, C_{6-10} arylamino, C_{6-10} aryloxy, C_{1-9} heteroaryl, C_{1-9} heteroaryloxy, C_{1-9} heteroaryl- C_{1-3} -alkyl, or C_{2-10} heterocyclyl;

each R^6 is independently H, deuterium, C_{1-4} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy- C_{1-4} -alkyl, C_{1-6} alkylamino- C_{1-4} -alkyl, or C_{1-6} alkylthio- C_{1-4} -alkyl; and

each n_1 and n_2 is independently 1, 2, 3 or 4.

8. The compound according to claim 1, wherein the R^3 , R^4 and X^2 -CH together form one of the following monovalent groups:






wherein each R^{15} is independently H, deuterium, F, Cl, Br, I, cyano, hydroxy, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy, C_{1-3} alkylamino, C_{1-3} alkylthio, C_{6-10} arylamino, C_{6-10} aryloxy, C_{1-9} heteroaryl, C_{1-9} heteroaryloxy, C_{1-9} heteroaryl- C_{1-3} -alkyl, or C_{2-10} heterocyclyl;

each R^6 is independently H, deuterium, C_{1-4} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} aminoalkyl, C_{1-6} alkoxy- C_{1-4} -alkyl, C_{1-6} alkylamino- C_{1-4} -alkyl, or C_{1-6} alkylthio- C_{1-4} -alkyl; and

each n_1 and n_2 is independently 1, 2, 3 or 4.

9. The compound according to claim 1 having Formula (II):





wherein each Q^1 and Q^2 is independently NR^6 , O, S, $C(=O)$ or CH_2 ;


each X^3 is independently O, S, NR^6 , $C(=O)$ or CR^7R^{7a} ;


each e is independently 0, 1, 2, 3 or 4 with the proviso that where X^3 is O, S or NR^6 , e is 1;

each Y^1 and Y^2 is independently N or CR^7 ;

each f is independently 0, 1, 2, 3 or 4;

each of A and A' is independently





each R^5 is independently H, deuterium, hydroxy, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{3-10} cycloalkyl, C_{2-10} heterocyclyl, C_{6-10} aryl, C_{1-9} heteroaryl, C_{6-10} aryl- C_{1-6} -alkyl, or C_{1-6} alkoxy;

each R^{5a} is independently H, deuterium, oxo ($=O$), hydroxy, amino, F, Cl, Br, I, cyano, C_{1-6} alkoxy, C_{1-6} alkyl, $-CF_3$, $-OCF_3$, nitro, C_{1-6} alkylamino, or C_{3-10} cycloalkyl;

each R^6 is independently H, deuterium, C_{1-6} aliphatic, C_{1-6} alkoxy- C_{1-6} -aliphatic, or C_{1-6} alkylamino- C_{1-6} -alkyl;

each R^{6a} is independently H, deuterium, oxo ($=O$), hydroxy, amino, F, Cl, Br, I, cyano, C_{1-6} alkylacyl, C_{1-6} alkylacyloxy, C_{1-6} alkoxyacyl, C_{1-6} alkoxy, C_{1-6} alkyl, C_{6-10} aryl, $-CF_3$, $-OCF_3$, mercapto, nitro, C_{1-6} alkylamino, C_{3-10} cycloalkyl or C_{6-10} aryloxy;

each R^7 and R^{7a} is independently H, deuterium, C_{1-6} aliphatic, C_{1-6} heteroalkyl, C_{1-6} alkoxy- C_{1-6} -aliphatic, or C_{1-6} alkylamino- C_{1-6} -aliphatic;


each of Y_4 and Y_4' is independently a bond, O, S, $-(CH_2)_n$, $-CH=CH-$, $-S(=O)_r$, $-CH_2O-$, $-CH_2S-$, $-CH_2S(=O)_r$, $-CF_2-$, $-CHR^{5a}-$ or $-CH_2N(R^6)-$;


each n is independently 0, 1, 2 or 3;

each p is independently 0, 1, 2 or 3; and

each r is independently 0, 1 or 2.

10. The compound according to claim 1 having Formula (II'):





wherein each Q^1 and Q^2 is independently NR^6 , O, S, $C(=O)$ or CH_2 ;


each X^3 is independently O, S, NR^6 , $C(=O)$ or CR^7R^{7a} ; e is 0, 1, 2, 3 or 4 with


the proviso that where X^3 is O, S or NR^6 , e is 1;

each X^5 is independently CR^7R^{7a} , O, S or NR^6 ;

each f is independently 0, 1, 2, 3 or 4;

each of A and A' is independently





each R^5 is independently H, deuterium, hydroxy, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{3-10} cycloalkyl, C_{2-10} heterocyclyl, C_{6-10} aryl, C_{1-9} heteroaryl, C_{6-10} aryl- C_{1-6} -alkyl, or C_{1-6} alkoxy;

each R^{5a} is independently H, deuterium, oxo (=O), hydroxy, amino, F, Cl, Br, I, cyano, C_{1-6} alkoxy, C_{1-6} alkyl, C_{6-10} aryl, $-CF_3$, $-OCF_3$, , nitro, C_{1-6} alkylamino, or C_{3-10} cycloalkyl;


each R^6 is independently H, deuterium, C_{1-6} alkyl, C_{1-6} alkoxy- C_{1-6} -alkyl, or C_{1-6} alkylamino- C_{1-6} -alkyl;

each R^{6a} is independently H, deuterium, oxo (=O), hydroxy, amino, F, Cl, Br, I, cyano, C_{1-6} alkylacyl, C_{1-6} alkylacyloxy, C_{1-6} alkoxyacyl, C_{1-6} alkoxy, C_{1-6} alkyl, C_{6-10} aryl, $-CF_3$, $-OCF_3$, mercapto, nitro, C_{1-6} alkylamino, C_{3-10} cycloalkyl or C_{6-10} aryloxy;

each R^7 and R^{7a} is independently H, deuterium, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{1-6} alkoxy- C_{1-6} -alkyl, or C_{1-6} alkylamino- C_{1-6} -alkyl;

each of Y_4 and Y_4' is independently a bond, O, S, $-(CH_2)_n-$, $-CH=CH-$, $-S(=O)_r-$, $-CH_2O-$, $-CH_2S-$, $-CH_2S(=O)_r-$, $-CF_2-$, $-CHR^{5a}-$ or $-CH_2N(R^6)-$.

11. The compound according to claim 9 having Formula (III):



wherein each Q^1 and Q^2 is independently O, S, $C(=O)$, NR^6 or CH_2 ;

X^3 is O, S, NR^6 , $C(=O)$ or CR^7R^{7a} ;


each R^6 is independently H, deuterium, C_{1-6} alkyl, C_{1-6} alkoxy- C_{1-6} -alkyl, or C_{1-6} alkylamino- C_{1-6} -alkyl;

each R^7 and R^{7a} is independently H, deuterium, C_{1-6} alkyl, C_{1-6} heteroalkyl, C_{1-6}

alkoxy-C₁₋₆-alkyl, or C₁₋₆ alkylamino-C₁₋₆-alkyl; and

f is 0, 1, 2, 3 or 4.

12. The compound according to claim 9 having Formula (IV):




wherein X³ is O, S, NR⁶, C(=O) or CR⁷R^{7a};

each R^{5a} is independently H, deuterium, oxo (=O), hydroxy, amino, F, Cl, Br, I, cyano, C₁₋₆ alkylacyl, C₁₋₆ alkylacyloxy, C₁₋₆ alkoxyacyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₆₋₁₀ aryl, -CF₃, -OCF₃, mercapto, nitro, C₁₋₆ alkylamino, C₃₋₁₀ cycloalkyl or C₆₋₁₀ aryloxy;

f is 0, 1, 2, or 3; and

each R⁷ and R^{7a} is independently H, deuterium, C₁₋₄ alkyl, C₁₋₄ heteroalkyl, C₁₋₆ alkoxyalkyl, or C₁₋₆ alkylaminoalkyl.

13. The compound according to claim 9 having Formula (V):




wherein X³ is O, S, NR⁶, C(=O) or CR⁷R^{7a};

each R^{5a} is independently H, deuterium, oxo (=O), hydroxy, amino, F, Cl, Br, I, cyano, C₁₋₄ alkylacyl, C₁₋₄ alkylacyloxy, C₁₋₄ alkoxyacyl, C₁₋₄ alkoxy, C₁₋₄ alkyl, C₆₋₁₀ aryl, -CF₃, -OCF₃, mercapto, nitro, C₁₋₆ alkylamino, C₃₋₈ cycloalkyl or C₆₋₁₀ aryloxy;

f is 0, 1, 2, or 3; and

each R⁷ and R^{7a} is independently H, deuterium, C₁₋₄ alkyl, C₁₋₄ heteroalkyl, C₁₋₆ alkoxyalkyl, or C₁₋₆ alkylaminoalkyl.

14. The compound according to claim 9 having Formula (VI):







wherein each Q^1 and Q^2 is independently O, S, C(=O), NR^6 or CH_2 ;

each R^{5a} is independently H, deuterium, oxo (=O), hydroxy, amino, F, Cl, Br, I, cyano, C_{1-4} alkylacyl, C_{1-4} alkylacyloxy, C_{1-4} alkoxyacyl, C_{1-4} alkoxy, C_{1-4} alkyl, C_{6-10} aryl, $-CF_3$, $-OCF_3$, mercapto, nitro, C_{1-6} alkylamino, C_{3-8} cycloalkyl or C_{6-10} aryloxy;

each R^6 is independently H, deuterium, C_{1-6} alkyl, C_{1-6} alkoxy- C_{1-6} -alkyl, or C_{1-6} alkylamino- C_{1-6} -alkyl; and

f is 0, 1, 2, 3 or 4.

15. The compound according to claim 10 having Formula (III'), or Formula (IV'), or Formula (V'), or Formula (VI') :



wherein each Q^1 and Q^2 is independently O, S, C(=O), NR^6 or CH_2 ;

X^3 is O, S, NR^6 , C(=O) or CR^7R^{7a} ;

f is 0, 1, 2 or 3;

X⁵ is CH₂, O, S or NR⁶;

each R^{5a} is independently H, deuterium, oxo (=O), hydroxy, amino, F, Cl, Br, I, cyano, C₁₋₄ alkylacyl, C₁₋₄ alkylacyloxy, C₁₋₄ alkoxyacyl, C₁₋₄ alkoxy, C₁₋₄ alkyl, C₆₋₁₀ aryl, -CF₃, -OCF₃, mercapto, nitro, C₁₋₆ alkylamino, C₃₋₈ cycloalkyl or C₆₋₁₀ aryloxy;

each R⁶ is independently H, deuterium, C₁₋₆ alkyl, C₁₋₆ alkoxy-C₁₋₆-alkyl, or C₁₋₆ alkylamino-C₁₋₆-alkyl; and

each R⁷ and R^{7a} is independently H, deuterium, C₁₋₄ alkyl, C₁₋₄ heteroalkyl, C₁₋₆ alkoxyalkyl, or C₁₋₆ alkylaminoalkyl.

16. The compound according to any one of claims 1 to 15, wherein each of Y and Y' is independently -U-(CR⁹R^{9a})_t-R¹² or -C(=O)-(CR⁹R^{9a})_t-R¹².

17. The compound according to claim 16, wherein each R⁹, R^{9a}, R¹⁰ and R¹¹ is independently H, deuterium, C₁₋₆ alkyl, C₁₋₆ heteroalkyl, C₃₋₁₀ cycloalkyl, C₂₋₁₀ heterocyclyl, C₆₋₁₀ aryl, C₁₋₉ heteroaryl, C₆₋₁₀ aryl-C₁₋₆-alkyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₉ heteroaryl-C₁₋₆-alkyl, C₂₋₁₀ heterocyclyl-C₁₋₆-alkyl, or C₃₋₈ cycloalkyl-C₁₋₆-alkyl;

each R¹² is independently -N(R¹³)C(=O)OR^{13a} or -N(R¹³)C(=O)-R^{13a};

each R¹³ is H; and


each R^{13a} is H, deuterium, C₁₋₆ alkyl, C₁₋₆ heteroalkyl, or C₂₋₁₀ heterocyclyl.

18. The compound according to claim 17, wherein each R⁹, R^{9a}, R¹⁰ and R¹¹ is independently H, deuterium, methyl, ethyl, isopropyl, cyclohexyl, isobutyl or phenyl;

each R¹³ is H; and

each R^{13a} is H, deuterium, methyl, ethyl, propyl, phenyl, morpholinyl or piperidinyl.


19. The compound according to claim 9 having Formula (VII):



wherein each of R^{14} and R^{14a} is independently H, deuterium, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{6-10} aryl, C_{1-9} heteroaryl, C_{2-10} heterocyclyl, C_{3-8} cycloalkyl, C_{6-10} aryl- C_{1-6} -alkyl, C_{1-9} heteroaryl- C_{1-6} -alkyl, C_{2-10} heterocyclyl- C_{1-6} -alkyl, or C_{3-8} cycloalkyl- C_{1-6} -alkyl;

wherein each of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{6-10} aryl, C_{1-9} heteroaryl, C_{2-10} heterocyclyl, C_{3-8} cycloalkyl, C_{6-10} aryl- C_{1-6} -alkyl, C_{1-9} heteroaryl- C_{1-6} -alkyl, C_{2-10} heterocyclyl- C_{1-6} -alkyl and C_{3-8} cycloalkyl- C_{1-6} -alkyl is optionally substituted with one or more substituents, wherein the substituent is deuterium, F, Cl, Br, hydroxy or cyano.

20. The compound according to claim 19 having Formula (VIII):



wherein each of R^{14} and R^{14a} is independently H, deuterium, C_{1-3} hydroxyalkyl, methyl, ethyl, isopropyl, isobutyl, *tert*-butyl, allyl, propargyl, trifluoroethyl, phenyl, pyranyl, morpholinyl, $-NR^7R^{7a}$, benzyl, piperazinyl, cyclopentyl, cyclopropyl, cyclohexyl, or C_{1-9} heteroaryl; wherein each of methyl, ethyl, isopropyl, isobutyl, *tert*-butyl, allyl, propargyl, trifluoroethyl, phenyl, pyranyl, morpholinyl, $-NR^7R^{7a}$,

benzyl, piperazinyl, cyclopentyl, cyclopropyl and cyclohexyl is optionally substituted with one or more substituents, wherein the substituent is deuterium, F, Cl, Br, hydroxy or cyano;


each Q^1 and Q^2 is independently NR^6 , O, S, $C(=O)$ or CH_2 ;


each Y^1 and Y^2 is independently N or CR^7 ;

each X^3 is independently O, S, NR^6 , $C(=O)$ or CR^7R^{7a} ; e is 0, 1, 2, or 3 with the proviso that where X^3 is O, S, $C(=O)$ or NR^6 , e is 1;

f is 0, 1, 2, 3 or 4;


each of A and A' is independently





each of Y_4 and Y_4' is independently a bond, O, S, $-(CH_2)_n-$, $-CH=CH-$, $-S(=O)_r-$, $-CH_2O-$, $-CH_2S-$, $-CH_2S(=O)_r-$, $-CF_2-$, $-CHR^{5a}-$ or $-CH_2N(R^6)-$.

21. The compound according to claim 1 having Formula (IX):




wherein each of R^{14} and R^{14a} is independently H, deuterium, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl, C_{6-10} aryl, C_{1-9} heteroaryl, C_{2-10} heterocyclyl, C_{3-8} cycloalkyl, C_{6-10} aryl- C_{1-6} -alkyl, C_{1-9} heteroaryl- C_{1-6} -alkyl, C_{2-10} heterocyclyl- C_{1-6} -alkyl or C_{3-8} cycloalkyl- C_{1-6} -alkyl; and

each n_2 is independently 1, 2, 3 or 4;

wherein each of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} heteroalkyl,

C₆₋₁₀ aryl, C₁₋₉ heteroaryl, C₂₋₁₀ heterocyclyl, C₃₋₈ cycloalkyl, C₆₋₁₀ aryl-C₁₋₆-alkyl, C₁₋₉ heteroaryl-C₁₋₆-alkyl, C₂₋₁₀ heterocyclyl-C₁₋₆-alkyl and C₃₋₈ cycloalkyl-C₁₋₆-alkyl is optionally substituted with one or more substituents, wherein the substituent is deuterium, F, Cl, Br, hydroxy or cyano.

22. The compound according to claim 1 having Formula (X):




wherein each Q¹ and Q² is independently CH₂, CF₂, O, C(=O) or NR⁶;

each of R¹⁴ and R^{14a} is independently H, deuterium, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxyalkyl, C₁₋₆ heteroalkyl, C₆₋₁₀ aryl, C₁₋₉ heteroaryl, C₂₋₁₀ heterocyclyl, C₃₋₈ cycloalkyl, C₆₋₁₀ aryl-C₁₋₆-alkyl, C₁₋₉ heteroaryl-C₁₋₆-alkyl, C₂₋₁₀ heterocyclyl-C₁₋₆-alkyl or C₃₋₈ cycloalkyl-C₁₋₆-alkyl; and

each n₁ is independently 1, 2, 3 or 4.


23. The compound according to claim 1 having Formula (XI):




wherein each R^{5a} is independently H, deuterium, methyl, ethyl, F, Cl, Br or I;

each of R¹⁴ and R^{14a} is independently H, deuterium, methyl, ethyl, phenyl, cyclohexyl, 1-methyl propyl, isopropyl or *tert*-butyl;


each of R¹⁶ and R^{16a} is independently hydroxy, methoxy, ethoxy, phenoxy,







wherein each of methyl, ethyl, phenyl, cyclohexyl, 1-methyl propyl, isopropyl, methoxy, ethoxy, *tert*-butoxy and *tert*-butyl is optionally substituted with one or more substituents, wherein the substituent is deuterium, F, Cl, Br, hydroxy or cyano;



each of A and A' is independently







wherein R^{5a} is H or methyl;

each of Q^1 and Q^2 is independently CH_2 , CF_2 , O, $C(=O)$ or NR^6 ;

each of Y^1 and Y^2 is independently N or CR^7 ;

R^7 is H, deuterium, methyl, ethyl, isopropyl, phenyl, F, Cl, Br, I, OH or cyano;

each of R^{14} and R^{14a} is independently H, deuterium, methyl, ethyl, isobutyl, cyclohexyl, phenyl or isopropyl;

each of R^{15} and R^{15a} is independently H, deuterium, F, Cl, Br, methyl, ethyl, isopropyl or *tert*-butyl;

each of R^{17} and R^{17a} is independently methyl, phenyl or ethyl;


each X^3 is independently O, S, NR^6 , $C(=O)$ or CH_2 ;

each R^6 is independently H, methyl, ethyl, or isopropyl;


e is 0, 1, 2 or 3 with the proviso that where X^3 is O, S, or NR^6 , e is 1;

wherein each of methyl, ethyl, phenyl, cyclohexyl, isopropyl and *tert*-butyl is optionally substituted with one or more substituents, wherein the substituent is deuterium, F, Cl, Br, hydroxy or cyano; and

each of A and A' is independently



25. The compound according to claim 1 having Formula (XII'):



wherein R^{5a} is H or methyl;

each of Q^1 and Q^2 is independently CH_2 , CF_2 , O, $C(=O)$ or NR^6 ;

X^5 is CH_2 , O, S or NR^6 ;

each of R^{14} and R^{14a} is independently H, deuterium, methyl, ethyl, isobutyl, cyclohexyl, phenyl or isopropyl;

each of R^{15} and R^{15a} is independently H, deuterium, F, Cl, Br, methyl, ethyl, isopropyl or *tert*-butyl;

each of R^{17} and R^{17a} is independently methyl, phenyl or ethyl;


each X^3 is independently O, S, NR^6 , $C(=O)$ or CH_2 ;

each R^6 is independently H, deuterium, methyl, ethyl or isopropyl;


e is 0, 1, 2 or 3 with the proviso that where X^3 is O, S, or NR^6 , e is 1;

















wherein each of methyl, ethyl, phenyl, cyclohexyl, isopropyl and *tert*-butyl is optionally substituted with one or more substituents, wherein the substituent is deuterium, F, Cl, Br, hydroxy or cyano; and










each of A and A' is independently





26. The compound of claim 1 having one of the following structures:














(57),




(58),




(59),




(60),




(61),




(62),




(63),




(64),




(65),




(66),




(67),




(68),





(69),





(70),

























or a stereoisomer, a geometric isomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof.

27. A pharmaceutical composition comprising a compound according to any one of claims 1 to 26; and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.

28. The pharmaceutical composition according to claim 27 further comprising an anti-HCV agent; wherein the anti-HCV agent is an interferon, ribavirin, IL-2, IL-6, IL-12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, imiquimod, an inosine-5'-monophosphate dehydrogenase inhibitor, amantadine, rimantadine, ribavirin, bavituximab, human hepatitis C immune globulin (CIVACIRTM), boceprevir, telaprevir, erlotinib, daclatasvir, simeprevir, asunaprevir, vaniprevir, faldaprevir, ABT-450, danoprevir, sovalprevir, MK-5172, vedroprevir, BZF-961, GS-9256,

narlaprevir, ANA975, ABT-267, EDP239, PPI-668, GS-5816, samatasvir (IDX-719), MK-8742, MK-8325, GSK-2336805, PPI-461, TMC-435, MK-7009, BI-2013335, ciluprevir, BMS-650032, ACH-1625, ACH-1095, VX-985, IDX-375, VX-500, VX-813, PHX-1766, PHX-2054, IDX-136, IDX-316, EP-013420, VBY-376, TMC-649128, R-7128, PSI-7977, INX-189, IDX-184, IDX102, R1479, UNX-08189, PSI-6130, PSI-938, PSI-879, HCV-796, HCV-371, VCH-916, VCH-222, ANA-598, MK-3281, ABT-333, ABT-072, PF-00868554, BI-207127, GS-9190, A-837093, JKT-109, GI-59728, GL-60667, AZd-2795, TMC647055 or a combination thereof; and wherein the interferon is interferon α -2b, pegylated interferon α , interferon α -2a, pegylated interferon α -2a, consensus interferon- α , or interferon γ .

29. The pharmaceutical composition according to claim 27 or 28 further comprising at least one HCV inhibitor, wherein the HCV inhibitor inhibits HCV viral protein, HCV replication or HCV viral protein and HCV replication, and wherein the HCV viral protein is helicase, proteinase, polymerase, metalloproteinase, serine proteinase, non-structural protein NS4A, non-structural protein NS5A, or non-structural protein NS4B, and wherein the HCV replication is HCV entry, HCV assembly, HCV egress, internal ribosome entrysites (IRES) or inosine-5'-monophosphate dehydrogenase (IMPDH).

30. Use of a compound according to any one of claims 1 to 26 in the manufacture of a medicament for preventing, managing, treating or lessening the severity of HCV infection or a HCV disorder.